Regd. Office: Nirmala Apartment, 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

Ref. : JPL/CS/1835/2022

Date: 01st December, 2022.

To,
The General Manager
BSE Limited
Corporate Relation Department
Phiroze Jeejeeboy Towers
14th Floor, Dalal Street,
Fort, Mumbai- 400 001
Scrip Code: 524731

Subject: Outcome of the Board Meeting held on 01st December, 2022.

Ref : Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations").

Dear Sir/Madam,

A. Approval of Buyback

Further to our intimation dated 28th November, 2022 and in terms of Regulation 30 of the SEBI Listing Regulations read with circular issued by SEBI bearing number CIR/CFD/CMD/4/2015 dated September 09, 2015 and other applicable provisions of law, we wish to inform you that the Board of Directors of **Jenburkt Pharmaceuticals Limited** (the "**Company**") at its meeting held on **01st December, 2022** has inter alia:

1. Approved a proposal to buyback by the Company of up to 165242 fully paid-up equity shares of face value of INR10/- (Indian Rupees Ten only) each (**"Equity Shares"**) at a price not exceeding INR 702/- (Indian Rupees Seven Hundred Two only) per Equity Share (the "**Maximum Buyback Price**") payable in cash for an aggregate amount not exceeding INR 11,60,00,000/- (Rupees Eleven Crore Sixty Lac only) (the "**Maximum Buy-back Size**"), from the shareholders of the Company excluding promoters, promoter group and persons who are in control of the Company, via the "Open Market" route through the stock exchanges mechanism, i.e., using the electronic trading facilities of the stock exchanges where the Equity Shares of the Company are listed (i.e., BSE Limited), in accordance with the provisions under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("**Buyback Regulations**") and the Companies Act, 2013 (including the rules and regulations framed thereunder), as amended, and other applicable provisions (the process hereinafter referred to as the "**Buyback**").

2. At the Maximum Buyback Price and for the Maximum Buyback Size, the indicative maximum number of Equity Shares bought back would be 165242 ("**Maximum Buyback Shares**") which is 3.60 % of the total number of paid-up Equity Shares of the Company. If the equity shares are bought back at a price below the Maximum Buyback Price, the actual number of equity shares bought back could exceed the indicative Maximum Buyback Shares (assuming full deployment

of Maximum Buyback Size) but will always be subject to the Maximum Buyback Size. Further, the Buyback shall not exceed the Maximum Buyback Size, which represents 9.96% of the aggregate of the total paid-up equity share capital and free reserves of the Company based on the latest audited standalone financial statements of the Company as on March 31, 2022 and is within the statutory limit of 10% of the aggregate of the fully paid-up equity share capital and free reserves of the Company under the board approval route under the Section 68(2)(b) of the Companies Act, 2013 and pursuant to the proviso to Regulation 5(i)(b) of Buyback Regulations.

Maximum Buyback Size shall not include any other expenses incurred or to be incurred for the Buyback like filing fees payable to SEBI, advisors' fees, stock exchange fee for usage of their platform for Buyback, brokerage, costs, fees, turnover charges, applicable taxes such as buyback tax, securities transaction tax, Goods and Services Tax (if any), stamp duty, etc., public announcement publication expenses and other incidental and related expenses and charges.

Unless otherwise permitted under applicable law, the Company shall utilize at least 50% of the Maximum Buyback Size i.e., **INR 5,80,00,000/- (Indian Rupees Five Crore Eighty Lac Only)** ("**Minimum Buyback Size**") towards the Buyback and accordingly, based on the Maximum Buyback Price and Minimum Buyback Size, the Company will purchase an indicative minimum number of 82622 Equity Shares.

The pre Buyback shareholding pattern of the Company is enclosed as **Annexure-A**.

3. The formation of a Buyback Committee and delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback.

4. Appointment of the Company Secretary as the "Compliance Officer" for the purpose of the Buyback.

5. DAM Capital Advisors Limited, a SEBI Registered Merchant Banker, has been appointed as the Manager to the Buyback.

6. The buy-back price of Rs. 702, is 20.01 % and 18.96 % over the volume weighted average price (VWAP) of the shares of the Company at BSE for three months and one month respectively prior to the date of intimation by the Company about the proposed buy-back submitted to the exchange i.e. 28th November, 2022.

   The public announcement setting out the process, timelines, and other requisite details will be released in due course in accordance with the Buyback Regulations,

   The above information will also be made available on the website of the Company www.jenburkt.com.

B. Appointment of Cost Auditor

We regret to inform you about the sad demise of Shri. Jagdish R. Bhavsar, Proprietor of M/s. Jagdish R. Bhavsar, Cost Accountants, the Cost Auditor of the Company.

To fill up the casual vacancy, the Board appointed M/s. Kirit Mehta & Co., (Firm Registration No.: 000353), Cost Accountants as the Cost Auditors of the Company with effect from 01st December, 2022, to conduct the cost audit of cost records maintained by the Company, for the financial year ended March 31, 2023, on the recommendation of Audit Committee, vide their meeting held on even date.

Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015 dated 09th September, 2015, is enclosed as **Annexure B**.

The Board Meeting commenced at 11.30 a.m. p.m. (IST) and concluded at 2.20 p.m. (IST)

You are requested to take the above information on record.

Thanking you,

Yours faithfully,

For Jenburkt Pharmaceuticals Limited

Ashish Rasiklal Shah

Digitally signed by Ashish Rasiklal Shah
DN: c=IN, o=Personal, postalCode=400058, st=Maharashtra, 2.5.4.20=8804c49d99c6fa43890acd3bc14eea334a17aa4ffad002d2ea91bb57579029c51, pseudonym=2AE3BFFFDB3201B9C36158120 1AA8FE793998B1E, serialNumber=81C6994C7850B335D2A3FCEA66B3389C0D82669D0F1140FA5E6935B40F8A9C0D, cn=Ashish Rasiklal Shah
Date: 2022.12.01 16:03:11 +05'30'

Ashish R. Shah
Company Secretary & Compliance Officer.

Annexure A

Shareholding pattern of the Company as on 01st December, 2022 (pre Buy-back), is given below:

Category	Pre-Buyback	
	No. of Equity Shares	% of Equity Shares
(A) Promoter & Promoter Group	2098788	45.73
(B) Public	2490590	54.27
(C1) Shares underlying DRs	0	0
(C2) Shares held by Employee Trust	0	0
(C) Non-Promoter-Non Public (C1+C2)	0	0
Grant Total (A+B+C)	4589378	100.00

Ashish Rasiklal Shah

Digitally signed by Ashish Rasiklal Shah
DN: c=IN, o=Personal, postalCode=400058, st=Maharashtra, 2.5.4.20=8804c49d96c6fa43890acd3bc14eea334a17a a4ffad002d2ee91b57579029c51, pseudonym=2AE3BFFFDB3201B9C361581201AA8FE793998B1E, serialNumber=81C6994C7850B335D2A3FCEA66B338 9C0D82669D0F1140FA5E6935B40F8A9C0D, cn=Ashish Rasiklal Shah
Date: 2022.12.01 16:04:29 +05'30'

Annexure B

Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015 dated 09th September, 2015.

Sr. No.	Particular	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of new Cost Auditors of the Company to fill the casual vacancy caused by the death of the Cost Auditor.
2.	Date of appointment/cessation & term of appointment;	01st December, 2022 for conducting Cost Audit of the cost records of the Company for the Financial Year 2022-23.
3.	Brief Profile;	The firm is engaged in cost and management accounting since last 46 years. Headed by Shri. Kirit Mehta. The firm is also engaged in various allied activites to serve its approx. 60+ corporate clients.
4.	Disclosure of relationships between directors.(In case of appointment of a director)	Not Applicable

Ashish Rasiklal Shah

Digitally signed by Ashish Rasiklal Shah
DN: c=IN, o=Personal, postalCode=400058, st=Maharashtra, 2.5.4.20=8804c49d96c6fa43890acd3bc14eea334a17aa4ffad002d2ee91b57579029c51, pseudonym=2AE3BFFFDB3201B9C361581201AA8FE793998B1E, serialNumber=81C6994C7850B335D2A3FCEA66B3389C0D82669D0F1140FA5E6935B40F8A9C0D, cn=Ashish Rasiklal Shah
Date: 2022.12.01 16:05:57 +05'30'